A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Patel Sandip P.; Othus Megan; Chae Young Kwang; Giles Francis J.; Hansel Donna E.; Singh Preet Paul; Fontaine Annette; Shah Manisha; Kasi Anup; Al Baghdadi Tareq; Matrana Marc; Gatalica Zoran; Korn W. Michael; Hayward Jourdain; McLeod Christine; Chen Helen X.; Sharon Elad; Mayerson Edward; Ryan Christopher W.; Plets Melissa; Blanke Charles; Kurzrock Razelle

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

【24h】

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

机译：双抗CTLA-4和罕见肿瘤（DART SWOG 1609）中的双抗CTLA-4和抗PD-1阻断的II篮试验中非致肿瘤患者（DART SWOG 1609）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Purpose: Immune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare tumors. We report the results of the ( nonpancreatic) neuroendocrine neoplasm cohort of SWOG S1609 dual anti- CTLA-4 and anti-PD-1 blockade in rare tumors (DART).

机译：目的：免疫检查点梗阻在肿瘤类型中改善了结果; 关于这些药剂在罕见肿瘤中的功效很少。我们在稀有肿瘤（DART）中报告了猪S1609双抗CTLA-4和抗PD-1阻断的（非Pancreatic）神经内分泌肿瘤群和抗PD-1阻断的结果。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2020年第10期|共7页
作者
Patel Sandip P.; Othus Megan; Chae Young Kwang; Giles Francis J.; Hansel Donna E.; Singh Preet Paul; Fontaine Annette; Shah Manisha; Kasi Anup; Al Baghdadi Tareq; Matrana Marc; Gatalica Zoran; Korn W. Michael; Hayward Jourdain; McLeod Christine; Chen Helen X.; Sharon Elad; Mayerson Edward; Ryan Christopher W.; Plets Melissa; Blanke Charles; Kurzrock Razelle;
展开▼
作者单位

Univ Calif San Diego Moores Canc Ctr La Jolla CA 92093 USA;

SWOG Stat Ctr Seattle WA USA;

Northwestern Univ Chicago IL 60611 USA;

Northwestern Univ Chicago IL 60611 USA;

Univ Calif San Diego La Jolla CA 92093 USA;

Heartland NCORP Springfield Clin Springfield IL USA;

New Mexico MU NCORP New Mexico Canc Ctr Albuquerque NM USA;

Ohio State Univ Comprehens Canc Ctr Alliance Clin Trials Oncol Columbus OH 43210 USA;

Univ Kansas Med Ctr Westwood KS USA;

Michigan CRC NCORP IHA Hematol Oncol Consultants Ypsilanti MI USA;

Ochsner Clin Fdn ECOG ACRIN New Orleans LA USA;

Caris Life Sci Tempe AZ USA;

Caris Life Sci Tempe AZ USA;

SWOG Data Operat Ctr Seattle WA USA;

SWOG Data Operat Ctr Seattle WA USA;

NCI Invest Drug Branch Canc Therapy Evaluat Program Bethesda MD 20892 USA;

NCI Invest Drug Branch Canc Therapy Evaluat Program Bethesda MD 20892 USA;

SWOG Stat Ctr Seattle WA USA;

Oregon Hlth &

Sci Univ Portland OR 97201 USA;

SWOG Stat Ctr Seattle WA USA;

Oregon Hlth &

Sci Univ Knight Canc Inst SWOG Grp Chairs Off Portland OR 97201 USA;

Univ Calif San Diego Moores Canc Ctr La Jolla CA 92093 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors [J] . Patel Sandip P., Othus Megan, Chae Young Kwang, Clinical cancer research: an official journal of the American Association for Cancer Research . 2020,第10期

机译：双抗CTLA-4和罕见肿瘤（DART SWOG 1609）中的双抗CTLA-4和抗PD-1阻断的II篮试验中非致肿瘤患者（DART SWOG 1609）
2. 270?A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the thyroid tumor cohort [J] . Young Kwang Chae, Megan Othus, Sandip Patel, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：270？在罕见肿瘤（DART）衍生S1609中的双抗CTLA-4和抗PD-1阻断的II篮子试验：甲状腺肿瘤队列
3. 795?A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) [J] . Michael Wagner, Megan Othus, Sandip Patel, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：795？在转移或不可切除的高管癌中的Ipilimumab和Nivolumab的多中心期II试验（播种S1609，COHORT 51）：在罕见肿瘤中替换双抗CTLA-4和抗PD-1阻断（DART）
4. Clinical studies of SP1049C, a polymer based anthracycline effective against drug resistant tumors. Results of phase II trial and pivotal phase Ⅲ program in upper gastrointestinal cancer indications [C] . Valery Alakhov Controlled Release Society Annual Meeting and Exposition . 2007

机译：SP1049C的临床研究，一种基于聚合物的蒽环类药物可有效抵抗耐药性肿瘤。上消化道癌适应症的II期试验和关键性III期试验结果
5. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518 [O] . James C. Yao, Katherine A. Guthrie, Cesar Moran, -1

机译：晚期类癌患者中奥曲肽+干扰素Alfa-2b与奥曲肽+贝伐单抗的III期前瞻性随机比较试验：SWOG S0518
6. A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors [O] . Sandip P. Patel, Megan Othus, Young Kwang Chae, 2020

机译：双抗CTLA-4和罕见肿瘤（DART SWOG 1609）中的双抗CTLA-4和抗PD-1阻断的II篮试验中非致肿瘤患者（DART SWOG 1609）

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅